Taysha Rett Program Updates Q2 2024

Taysha Gene Therapies is conducting, in parallel, two clinical trials to test their gene therapy, TSHA-102, in Rett syndrome. One trial, taking place in Canada and the US is for ages 12 years and older and a pediatric trial in the US, UK and now Canada for ages 5 to 8 years old with a later expansion to include 3 to 5 years old.

Today the company released the following information. For additional details we encourage you to read the Community Letter and Press Release.

• Interim safety data from the first participant in the adolescent/adult trial who received the high dose level showed that it was generally well-tolerated with no serious adverse events
• Two additional patients are set to receive high dose, an adolescent/adult patient and a pediatric patient
• Health Canada has approved a pediatric trial
• Efficacy data will be shared in the first half of 2025